Obesity Management: Optimizing Care of Your Patients
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of this educational activity, learners will be able to:
- Describe the role of hormonal and neural mechanisms in the regulation of appetite, food intake, and body weight
- Recognize the behavioral approaches to obesity management that are most impactful in practice
- Describe the mechanism of action, safety, and efficacy of new medical therapies for obesity
- Explain the comparative effectiveness of the surgical treatments for obesity, including what is known about mechanisms of action
- Develop an approach to choosing a treatment strategy that is most optimal for managing obesity
Endocrinologists, internists, endocrine nurses, and other allied health professionals who treat patients with obesity.
STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to The Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Ken Fujioka, MD: Research Support, Novo Nordisk; Consultant, Eisai, Gelesis, KVK-tech, Novo Nordisk, Orexigen; Speaker, Novo Nordisk, Orexigen, Takeda
The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: Connie Newman, MD
The following SPC Committee members reported financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, DexCom, Lexicon Medtronic, Novo Nordisk, Sanofi Aventis; Consultant, Novo Nordisk, Eli Lilly, Janssen, Dexcom
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
E Michael Lewiecki, MD: Advisory Board, Amgen, Merck, Eli Lilly, Radius Health, Shire, and Alexion; Speaker, Shire; Research Grant Support, Amgen, Eli Lilly, Merck
Alan Kelly, MD: Research Support, Novo Nordisk; Speaker, Novo Nordisk, Boehringer Ingelheim
Lisa Nachtigall, MD: Consultant, Pfizer, Chiasma
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim, Pfizer
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The following SPC members reported no relevant financial relationships: Giuseppe Barbesino, MD; Natalie Cusano, MD; Joan Han, MD; Amy Rothberg, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider's examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Novo Nordisk Inc and Ethicon Endo-Surgery, Inc.
AMA PRA CATEGORY 1 CREDIT™ (CME) INFORMATION
This enduring material is presented in an online recorded-session format. The estimated time to complete this activity, including review of material, is 1.0 hours. To receive a maximum of 1.0 AMA PRA Category 1 Credits™ participants must complete an activity evaluation, as well as a(n) answer sheet or post-test achieving a minimum score of 65%. If learners do not achieve a passing score of 65%, they have the option to retake the post-test.
To claim your CME credit, please follow these steps:
- Carefully review information about the CME credit activity prior to viewing presentations.
- View all of the presentations in the session where CME is being offered.
- Select the "Show CME" button in the media player to open an overlay with information on how to earn CME.
- Select the link to complete the post-test, if you are not signed in to endosessions.org, you will be prompted to sign-in or create a new account. You must earn a passing score of 65% in order to earn credit from the activity. You may retake a post-test as many times as necessary in order to pass.
- Complete the evaluation
- Print your certificate
If you experience any difficulty claiming CME, please contact the Endocrine Society at education.endocrine.org/contact.
Your system must meet the following requirements:
Computer: with minimum processor and memory as recommended by operating system manufacturer
Operating System: Windows: Vista, 7, 8, 10. Macintosh OSX
Internet Browser: consult the detailed system requirements page to determine the browser version required by Adobe Flash on your computer’s operating system.
Players & Plugins: an up-to-date version of Adobe Flash Player
Audio: Functioning sound card with attached speakers installed
Internet Connection: a broadband Internet connection
Please review the detailed system requirements page for more information and troubleshooting steps.
LAST REVIEW DATE: September 9, 2016
ACTIVITY RELEASE DATE: September 2016
ACTIVITY EXPIRATION DATE: September 30, 2017 (date after which this enduring material is no longer certified for AMA PRA Category 1 Credits™)
For technical assistance or information, please contact firstname.lastname@example.org.
For questions about content or obtaining CME credit, please contact the Endocrine Society at education.endocrine.org/contact.